WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 23-May-2016 (Data received as of 20-May-2016)
Next overall update Fall 2016
2015 data are provisionary
EPI mother and child logo         
Select a country

Development status: Least developed GNI / capita (US$): 2501 Infant (under 12 months) mortality rate: 432
GDP / capita (US$): 8151 Child (under 5 years) mortality rate: 642

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 17'215  16'695  16'190  15'700  15'227  11'193  9'409  6'163 
Births 665  653  640  629  618  497  446  325 
Surviving infants 629  616  603  590  578  440  381  275 
Pop. less than 5 years 2'954  2'895  2'845  2'796  2'734  2'043  1'752  1'209 
Pop. less than 15 years 7'774  7'573  7'381  7'196  7'011  5'251  4'307  2'912 
Female 15-49 years 3'961  3'820  3'681  3'546  3'417  2'443  2'196  1'386 

Number of reported cases

(Click for retrospective incidence data for Malawi)
Diphtheria
ChartChart
  13 
Japanese encephalitis
ChartChart
 
Measles
ChartChart
  11  26  304  162'686 
Mumps
ChartChart
 
Pertussis
ChartChart
  365  29'769 
Polio*
ChartChart
  70 
Rubella
ChartChart
  99  433  23  56  267 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  12  211  163 
Tetanus (total)**
ChartChart
  12  461 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Malawi)
Vaccine year result method % card seen                                                
BCG 2009  97  DHS   81  90  97  96  99  99  83  84  99 
DTP1 2009  97  DHS   81  93  97  96  99  98  98 
DTP3 2009  93  DHS   81  88  91  89  96  97  75  80  58 
DTP4         
IPV1         
HepB_BD         
HepB3 2009  93  DHS   81  88  91  89  96  97 
Hib3 2009  93  DHS   81  88  91  89  96  97 
JapEnc         
MCV1          87  85  88  90  96  73  81  49 
MCV2         
PCV1          93  96  96  99  39 
PCV3          88  87  89  99 
Pol3 2009  86  DHS   81  88  87  89  95  97  73  93  28 
Rota1          88  89  87  19 
RotaC         
Rubella1         
TT2plus 1994  77  MICS   88  54  90  65  71  79  61  76 
PAB         
VAD1          25  28  32  61  25  75 
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Malawi)
BCG
ChartChart
  97  96  99  99  83  97 
DTP1
ChartChart
  97  96  99  98  98  95  80 
DTP3
ChartChart
  91  89  96  97  75  87  58 
HepB3
ChartChart
  91  89  96  97 
HepB_BD
ChartChart
 
Hib3
ChartChart
  91  89  96  97 
MCV1
ChartChart
  85  88  90  96  73  81  49 
MCV2
ChartChart
 
PAB
ChartChart
  89  89  89  87  84  81 
PCV3
ChartChart
  87  89  99 
Pol3
ChartChart
  87  89  95  97  73  93  28 
RotaC
ChartChart
  83  81 

Number of districts in the country 28  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 50
From 80 to 89% 25
From 50 to 79% 21
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
4
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwPHibHepB 6, 10, 14 weeks; Yes
HPV 10 years; Yes girls aged 9-13 years
IPV 14 weeks; From October 2016
Measles 9, 15 months; Yes
OPV 6, 10, 14 weeks; Yes
Pneumo_conj 6, 10, 14 weeks; Yes
Rotavirus 6, 10 weeks; Yes
TT 1st contact; +1, +6 months; +1, +1 year; Yes pregnant women and CBAW
VitaminA 6, 12, 18, 24, 30, 36 months; Yes and postpartum

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2012-2016  2012-2016  2012-2016  2012-2016  2010-2014  2010-2014  2006-2010 
Nº of districts with microplans that include activities to raise immunization coverage number 28  28  28  28  28  28  26 

System performance

Total Nº districts in country number 28  28  28  28  28  28  26 
Nº districts with DTP3 coverage >=80% number 25  21  26  28  28  27  25 
% of districts with DTP3 coverage >=80% From 0 to 100% 89  75  93  100  100  96  96 
Nº districts with measles (MCV1) coverage >=95% number 11  15  16 
% of districts with MCV1 coverage >=95% From 0 to 100% 32  29  39  54  57  29  19 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  No  No     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 10  53      32  50   

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  No     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.